Trials needed to assess whether metformin impedes aneurysm progression in non-diabetic patients


Ronald Dalman (Stanford, USA) and Kak Khee Yeung (Amsterdam, The Netherlands) talk to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about how the use of metformin may help suppress the progression of abdominal aortic aneurysms (AAA).

Dalman points out that initial observations on metformin has shown it to be a possible agent in preventing AAA progression. He underlines however that questions remain about the safety and tolerability of using metformin in non-diabetic patients and discusses the need for clinical trials to assess these issues.

Yeung looks at the benefits of metformin and discusses her own cell-specific analysis which has shown that the medication has an anti-inflammatory effect and “stimulates cell proliferation”. Yeung notes that her own research points to metformin having an effect both on patients without diabetes as well as those with the condition.

Subscribe to receive BLearning videos here:


Please enter your comment!
Please enter your name here